Céline Loinard, Alexandre Ribault, Bruno Lhomme, Marc Benderitter, Stéphane Flamant, and Radia Tamarat, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE, Fontenay-aux-Roses, France.
Sandrine Paul & Valérie Dubois, EFS Auvergne Rhône Alpes, laboratoire HLA, 111, rue Elisée-Reclus, Lyon, 69150, Décines, France.
Ruenn Chai Lai & Sai Kiang Lim, Institute of Medical Biology A*STAR, #05-16 Immunos, & Institute of Molecular and Cellular Biology, A*STAR, #05-38 Immunos, 8 A Biomedical Grove, Singapore, 138648, Singapore.
HuMSC-EV induce monocyte/macrophage mobilization to orchestrate neovascularization in wound healing process following radiation injury
This study aims to investigate the mechanisms of human mesenchymal stem cell-derived extracellular vesicles (HuMSC-EV)-induced proangiogenic paracrine effects after radiation injury. HuMSC-EV were locally administered in mice hindlimb following 80-Gy X-ray irradiation and animals were monitored at different time points. HuMSC-EV improved neovascularization of the irradiated tissue, by stimulating angiogenesis, normalizing cutaneous blood perfusion, and increasing capillary density and production of proangiogenic factors. HuMSC-EV also stimulated vasculogenesis by promoting the recruitment and differentiation of bone marrow progenitors. Moreover, HuMSC-EV improved arteriogenesis by increasing the mobilization of monocytes from the spleen and the bone marrow and their recruitment into the muscle, with a pro-inflammatory potential. Importantly, monocyte depletion by clodronate treatment abolished the proangiogenic effect of HuMSC-EV. The critical role of Ly6C(hi) monocyte subset in HuMSC-EV-induced neovascularization process was further confirmed using Ccr2−/− mice. This study demonstrates that HuMSC-derived EV enhances the neovascularization process in the irradiated tissue by increasing the production of proangiogenic factors, promoting the recruitment of vascular progenitor cells, and the mobilization of innate cells to the injured site. These results support the concept that HuMSC-EV might represent a suitable alternative to stem cells for therapeutic neovascularization in tissue repair.